AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28490353 — intervention group
Group type: EXPERIMENTAL
Intervention: Both layouts (scrolling and paging)
Number of subjects: 530
Study 26178508 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-field dIMRT
Number of subjects: 30
Study 26178508 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-field dIMRT
Number of subjects: 30
Study 26178508 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-field dIMRT
Number of subjects: 30
Study 22669334 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) at increasing doses (2 gr/day) for 5-15 days prior to surgical resection
Number of subjects: 12
Study 22669334 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 12
Study 22669334 — intervention group
Group type: COMPARATOR
Intervention: Non-treated control group of 6 patients
Number of subjects: 12
Study 25155815 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (CBT) for 9 weeks
Number of subjects: 19
Study 25155815 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 19
Study 19685520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary bone marrow stem cell (BMSC) transfer at 4 to 7 days post-AMI
Number of subjects: 660
Study 19685520 — intervention group
Group type: COMPARATOR
Intervention: Emergent transfer (within 24 hours post-AMI)
Number of subjects: 660
Study 19685520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary bone marrow stem cell (BMSC) therapy at 4 to 7 days
Number of subjects: 660
Study 16508028 — intervention group
Group type: EXPERIMENTAL
Intervention: E-health innovations including videoconferencing, telephone, secure messaging (e-mail), and the Internet for psychiatric consultation-liaison service.
Number of subjects: 0
Study 16508028 — intervention group
Group type: COMPARATOR
Intervention: Successful models of service delivery used in suburban and urban settings.
Number of subjects: 0
Study 15587828 — intervention group
Group type: EXPERIMENTAL
Intervention: 100g OGTT
Number of subjects: 248
Study 15587828 — intervention group
Group type: COMPARATOR
Intervention: 75g OGTT
Number of subjects: 248
Study 15587828 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both OGTTs
Number of subjects: 248
Study 10793164 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of oral xemilofiban
Number of subjects: 7232
Study 10793164 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of oral xemilofiban
Number of subjects: 7232
Study 10793164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7232
Study 9395803 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 50 mg as a 1 ml injection 1 to 2 hours before operation
Number of subjects: 40
Study 9395803 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 1 ml intramuscularly before operation
Number of subjects: 40
Study 9395803 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 50 mg as a 1 ml injection immediately after surgery
Number of subjects: 40
Study 9395803 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 1 ml intramuscularly immediately after surgery
Number of subjects: 40
Study 9395803 — intervention group
Group type: COMPARATOR
Intervention: Total dose of pethidine given
Number of subjects: 40
Study 7954480 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 150 mg twice daily (b.i.d.)
Number of subjects: 178
Study 7954480 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 300 mg three-times-daily (t.i.d.)
Number of subjects: 178
Study 7954480 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 450 mg three-times-daily (t.i.d.)
Number of subjects: 178
Study 7954480 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 150 mg b.i.d. and t.i.d. groups
Number of subjects: 178
Study 7954480 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 178
Study 2955804 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 15 micrograms kg-1
Number of subjects: 0
Study 2955804 — intervention group
Group type: COMPARATOR
Intervention: 0.5% Halothane
Number of subjects: 0
Study 29305282 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi Five Intervention
Number of subjects: 43
Study 28736944 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox treatment
Number of subjects: 8
Study 26247037 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful PTA group (58 patients)
Number of subjects: 198
Study 26247037 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsuccessful PTA group (75 patients)
Number of subjects: 198
Study 26247037 — intervention group
Group type: COMPARATOR
Intervention: Control group (65 patients, with diabetes but no PAD)
Number of subjects: 198
Study 26247037 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin allele G20210A
Number of subjects: 198
Study 26247037 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR 677 or 1298 alleles
Number of subjects: 198
Study 23942527 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid natural orifice translumenal endoscopic surgery (NOTES) colectomy (HNC)
Number of subjects: 70
Study 23942527 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic colectomy (CL)
Number of subjects: 70
Study 21348024 — intervention group
Group type: EXPERIMENTAL
Intervention: Velband as tourniquet underpadding
Number of subjects: 100
Study 21348024 — intervention group
Group type: COMPARATOR
Intervention: Limb drapes as underpadding
Number of subjects: 100
Study 19058660 — intervention group
Group type: EXPERIMENTAL
Intervention: Race similarity (RS)
Number of subjects: 126
Study 19058660 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactivity
Number of subjects: 126
Study 19058660 — intervention group
Group type: EXPERIMENTAL
Intervention: Race similarity (RS) and Proactivity interaction
Number of subjects: 126
Study 19058660 — intervention group
Group type: EXPERIMENTAL
Intervention: Race-related fraternal relative deprivation (RD)
Number of subjects: 126
Study 19058660 — intervention group
Group type: EXPERIMENTAL
Intervention: Roles in mentoring dyads
Number of subjects: 126
Study 17156002 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 124
Study 17156002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cantharidin
Number of subjects: 124
Study 17156002 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid and lactic acid
Number of subjects: 124
Study 17156002 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod
Number of subjects: 124
Study 12681035 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery non-scalpel vasectomy (ENSV)
Number of subjects: 325
Study 12681035 — intervention group
Group type: COMPARATOR
Intervention: Marie Stopes scalpel vasectomy procedure
Number of subjects: 325
Study 10736656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac Molar
Number of subjects: 105
Study 10736656 — intervention group
Group type: COMPARATOR
Intervention: Dyract
Number of subjects: 105
Study 7483868 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric nutrition (glucose or xylitol/sorbitol-amino acid solutions)
Number of subjects: 44
Study 7483868 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 44
Study 7483868 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 44
Study 7483868 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol/sorbitol solution
Number of subjects: 44
Study 2090557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (group A)
Number of subjects: 62
Study 2090557 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (group B)
Number of subjects: 62
Study 2090557 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast CKMB release group
Number of subjects: 62
Study 2090557 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversibility observed in 21/62 patients (34%)
Number of subjects: 62
Study 2090557 — intervention group
Group type: COMPARATOR
Intervention: Patients not showing redistribution of thallium-201
Number of subjects: 62
Study 2090557 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast CKMB release
Number of subjects: 62
Study 2090557 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow CKMB release
Number of subjects: 62
Study 376036 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine 2.5 mg twice daily
Number of subjects: 47
Study 376036 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 47
Study 30651109 — intervention group
Group type: EXPERIMENTAL
Intervention: Actively trained classifiers
Number of subjects: 0
Study 30651109 — intervention group
Group type: COMPARATOR
Intervention: Passively trained classifiers with computational adaptation in a virtual environment
Number of subjects: 0
Study 28856940 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rGH) (0.4 mg injection daily)
Number of subjects: 17
Study 28856940 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 25997707 — intervention group
Group type: EXPERIMENTAL
Intervention: JE+rabies-accelerated (n = 217)
Number of subjects: 440
Study 25997707 — intervention group
Group type: COMPARATOR
Intervention: JE-standard (n = 56)
Number of subjects: 440
Study 25997707 — intervention group
Group type: COMPARATOR
Intervention: JE+rabies-standard (n = 167)
Number of subjects: 440
Study 23789216 — intervention group
Group type: EXPERIMENTAL
Intervention: Qi-regulating, chest-relaxing and blood-activating therapy integrated with some Western Medicines
Number of subjects: 0
Study 23789216 — intervention group
Group type: COMPARATOR
Intervention: Simple and conventional Western Medicine alone
Number of subjects: 0
Study 21479913 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg combined with vitamin D(3) 5,600 IU
Number of subjects: 515
Study 21479913 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 515
Study 18379369 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with reduced-dose carboplatin (AUC 3) and gemcitabine (1250 mg/m on days 1 and 8)
Number of subjects: 1
Study 18379369 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with gemcitabine and low-dose carboplatin
Number of subjects: 1
Study 16824148 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX)
Number of subjects: 20
Study 16824148 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) combined with medium-dose amphotericin B (AMB)
Number of subjects: 20
Study 12615559 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of melatonin taken at bedtime for 4 weeks
Number of subjects: 40
Study 12615559 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo taken at bedtime for 4 weeks
Number of subjects: 40
Study 11789225 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Chinese herbal medicine combined with synchronous radio- and chemotherapy) in group A
Number of subjects: 134
Study 11789225 — intervention group
Group type: COMPARATOR
Intervention: Synchronous radio- and chemotherapy in group B
Number of subjects: 134
Study 11789225 — intervention group
Group type: COMPARATOR
Intervention: Non-synchronous radio- and chemotherapy in group C
Number of subjects: 134
Study 9212969 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (Group H)
Number of subjects: 8
Study 9212969 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 8
Study 8273637 — intervention group
Group type: EXPERIMENTAL
Intervention: IV glucagon (1 mg)
Number of subjects: 349
Study 8273637 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg oral hyoscyamine sulfate
Number of subjects: 349
Study 8273637 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg oral hyoscyamine sulfate
Number of subjects: 349
Study 8273637 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 349
Study 2447432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (20 mg)
Number of subjects: 29
Study 2447432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 30265562 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from flash glucose monitoring to real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 40
Study 30265562 — intervention group
Group type: COMPARATOR
Intervention: Continuing with RT-CGM for an additional 8 weeks
Number of subjects: 40
Study 30265562 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from flash to RT-CGM
Number of subjects: 40
Study 29952503 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling
Number of subjects: 50
Study 24582471 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate hypercaloric tube-fed diet (HC/HC)
Number of subjects: 24
Study 24582471 — intervention group
Group type: COMPARATOR
Intervention: Control (isocaloric tube-fed diet)
Number of subjects: 24
Study 24582471 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat hypercaloric tube-fed diet (HF/HC)
Number of subjects: 24
Study 22633226 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) injections administered immediately following PNA and at 6 weeks and 3 months after the procedure.
Number of subjects: 47
Study 22633226 — intervention group
Group type: COMPARATOR
Intervention: No injections (control group).
Number of subjects: 47
Study 20555294 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 389
Study 18986065 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving target with a stationary object aligned with its initial location
Number of subjects: 0
Study 18986065 — intervention group
Group type: COMPARATOR
Intervention: Moving target without a stationary object
Number of subjects: 0
Study 15932522 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabinoids
Number of subjects: 0
Study 15932522 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 12874489 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine syrup 0.10 to 0.20 mg/day
Number of subjects: 67
Study 12874489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 10537782 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with benzoporphyrin derivative
Number of subjects: 0
Study 10537782 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with tin ethyl etiopurpurin
Number of subjects: 0
Study 10537782 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8604626 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg twice daily
Number of subjects: 56
Study 8604626 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 56
Study 1429475 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual dawn simulation (2.5-hour duration)
Number of subjects: 9
Study 1429475 — intervention group
Group type: COMPARATOR
Intervention: Rapid dawn simulation (10-minute duration)
Number of subjects: 9
Study 4044104 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine trial (5 mg caffeine/kg body weight)
Number of subjects: 8
Study 4044104 — intervention group
Group type: COMPARATOR
Intervention: Control trial (decaffeinated, calorie-free cola)
Number of subjects: 8
Study 4044104 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine trial
Number of subjects: 8
Study 29052245 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic and peanut oral immunotherapy (PPOIT)
Number of subjects: 51
Study 29052245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 27530657 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium 200 µg daily as selenized yeast
Number of subjects: 1621
Study 27530657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1621
Study 23963309 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose drospirenone/estradiol (0.25 mg/0.5 mg and 0.5 mg/0.5 mg)
Number of subjects: 383
Study 23963309 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (0.3 mg)
Number of subjects: 383
Study 23963309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study 22882843 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin loading before PCI (20 mg 12 hours before procedure, 10 mg 2 hours before procedure)
Number of subjects: 117
Study 22882843 — intervention group
Group type: COMPARATOR
Intervention: No rosuvastatin treatment before PCI (control group)
Number of subjects: 117
Study 22882843 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin loading before PCI
Number of subjects: 117
Study 20156339 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized intervention combining web-based tailored lifestyle advice and personal counselling by a lifestyle coach
Number of subjects: 400
Study 20156339 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 400
Study 18216475 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream applied twice daily for 8 weeks
Number of subjects: 20
Study 15591112 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT) after myeloablative radiochemotherapy
Number of subjects: 122
Study 15591112 — intervention group
Group type: COMPARATOR
Intervention: Alpha-interferon maintenance (IFN alpha)
Number of subjects: 122
Study 15591112 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 122
Study 12851096 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait test with burden
Number of subjects: 186
Study 12851096 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair-climbing test
Number of subjects: 186
Study 12851096 — intervention group
Group type: EXPERIMENTAL
Intervention: PILE cervical test
Number of subjects: 186
Study 12851096 — intervention group
Group type: EXPERIMENTAL
Intervention: All tests
Number of subjects: 186
Study 12851096 — intervention group
Group type: EXPERIMENTAL
Intervention: Less fit subjects
Number of subjects: 186
Study 10226898 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)-based immunosuppression
Number of subjects: 85
Study 10226898 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CYA)-based immunosuppression
Number of subjects: 85
Study 8556396 — intervention group
Group type: EXPERIMENTAL
Intervention: Early zidovudine treatment (n = 170)
Number of subjects: 275
Study 8556396 — intervention group
Group type: COMPARATOR
Intervention: Later zidovudine treatment (n = 168)
Number of subjects: 275
Study 8556396 — intervention group
Group type: EXPERIMENTAL
Intervention: Early zidovudine treatment
Number of subjects: 275
Study 8556396 — intervention group
Group type: COMPARATOR
Intervention: Later zidovudine treatment
Number of subjects: 275
Study 8556396 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving zidovudine for more than the median duration (20.3 months)
Number of subjects: 275
Study 1853191 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week exercise-based cardiac rehabilitation programme
Number of subjects: 22
Study 1853191 — intervention group
Group type: COMPARATOR
Intervention: Routine care group
Number of subjects: 22
Study 6756774 — intervention group
Group type: EXPERIMENTAL
Intervention: T-Cu 380A
Number of subjects: 328
Study 6756774 — intervention group
Group type: COMPARATOR
Intervention: Lippes loop C
Number of subjects: 328
Study 31969652 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard and strengthened care management (LA.S.S)
Number of subjects: 1419
Study 31969652 — intervention group
Group type: COMPARATOR
Intervention: Standard care management (A.S)
Number of subjects: 1419
Study 31969652 — intervention group
Group type: COMPARATOR
Intervention: Standard care management (LA.S)
Number of subjects: 1419
Study 30717034 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions related to management of hydrocephalus (e.g., shunt techniques, endoscopic treatment)
Number of subjects: 0
Study 30717034 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered outcomes (e.g., neurodevelopmental assessment, quality of life)
Number of subjects: 0
Study 29483383 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongxinluo capsules (TCs)
Number of subjects: 136
Study 29483383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 26856504 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-delivered reflexology
Number of subjects: 551
Study 24150216 — intervention group
Group type: EXPERIMENTAL
Intervention: F-SHAI (SHAI with fludarabine, 15 mg/m(2), 4 h before cytarabine)
Number of subjects: 326
Study 24150216 — intervention group
Group type: COMPARATOR
Intervention: SHAI (cytarabine, 1 g/m(2) bid, days 1‐2 and 8‐9; idarubicin 10 mg/m(2) daily, days 3‐4 and 10‐11)
Number of subjects: 326
Study 24150216 — intervention group
Group type: EXPERIMENTAL
Intervention: F-SHAI
Number of subjects: 326
Study 24150216 — intervention group
Group type: COMPARATOR
Intervention: SHAI
Number of subjects: 326
Study 22215436 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical peer models
Number of subjects: 60
Study 22215436 — intervention group
Group type: COMPARATOR
Intervention: Non-peer models
Number of subjects: 60
Study 20837887 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (5.4 mg)
Number of subjects: 31
Study 20837887 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg)
Number of subjects: 31
Study 20837887 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pyridostigmine and yohimbine
Number of subjects: 31
Study 17652682 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Scope
Number of subjects: 200
Study 17652682 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 200
Study 16135590 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment (single intramuscular injection of cefoxitin and oral doxycycline)
Number of subjects: 831
Study 16135590 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment (intravenous cefoxitin and doxycycline)
Number of subjects: 831
Study 16135590 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 831
Study 11856590 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with stem cell support
Number of subjects: 0
Study 11856590 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy in adjuvant setting
Number of subjects: 0